I'm an ICREA Research Professor at Pompeu Fabra University. My laboratory is focused in leveraging new gene editing technologies for therapeutic purposes. Our two main lines of research are mammalian genome engineering (ERC consolidator grant SCRIBE) and skin microbiome engineering (EIC pathfinder SKINDEV). In 2021, we launched Integra Therapeutics to combine the power of CRISPR technologies and transposasses for efficient gene writing of mammalian genomes (integra-tx.com).I received the National Research Prize to the Young talent (2018), named highly cited researcher (2019), elected EMBO Young Investigator (2020), received the August Pi i Sunyer award (2021) and received the National Research Prize Ángela Ruiz Robles (2022).I was previously a Wyss Technology Development Fellow at the Wyss Institute (mentor: George Church, Harvard Medical School) where I developed gene editing technologies to create biocontained safe recoded microorganims and engineered pigs for xenotransplantation. I've spent an important part of my time in translational science. I'm the founding scientist of eGenesis, a company aimed to provide an unlimited source of organs for transplantation, and cofounder of sbiomedic, a company developing novel therapeutic solutions using the skin microbiome.​I was initially trained as an Organic Chemist and as a Technical Engineer in Telecommunications. I started my PhD research at EMBL, but after the first year, I moved to the Centre for Genomic Regulation together with my group, where we continued our research in M. pneumoniae. My PhD research was centered in the use of high throughput technologies such as tiling arrays and next generation sequencing to characterize M. pneumoniae's transcriptome. We focused our efforts in understanding operon structure/dynamics and antisense transcription. We also developed a protocol for strand-specific transcriptome mapping.